View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 23, 2021

Roche records 8% increase in group sales for H1 2021

Sales in the Pharmaceuticals Division dropped by 3% in H1 2021 due to the impact of biosimilars.

Roche has reported an 8% increase in group sales to $33.46bn (CHF30.71bn) at constant exchange rates (CER) in the first half (H1) of 2021, as against $31.81bn (CHF29.28bn) in H1 last year.

The rise in group sales was 5% in Swiss currency for six months ended 30 June 2021.

In the Pharmaceuticals Division, sales decreased by 3% to $23.54bn (CHF21.67bn) in H1 2021 from $25.2bn (CHF23.2bn) last year due to the continued impact of biosimilars, especially in the US.

Roche noted that the pharmaceutical sales in the first quarter (Q1) of 2021 witnessed a 9% decline owing to the Covid-19 pandemic but rose by 4% in the second quarter (Q2) indicating a recovery in certain territories.

Furthermore, recent therapies launched since 2012 boosted sales by 30% to compensate for the impact of biosimilars.

For H1 2021, these treatments made sales of more than $11.96bn (CHF11bn), resulting in more than 50% of the total pharmaceutical sales.

In the US, sales declined by 8% due to the biosimilar launches for the cancer therapies MabThera/Rituxan, Avastin and Herceptin, and as well as the Covid-19 situation.

Sales in Europe and the international region rose by 4% and 2%, respectively, while sales in Japan were reported to be stable.

According to Roche, a significant development in the Q2 of 2021 was Tecentriq’s approval in the European Union for the treatment of a particular type of metastatic non-small cell lung cancer.

In addition, antibody combination, Ronapreve, developed jointly with Regeneron secured approval earlier this week in Japan for treating Covid-19.

Roche CEO Severin Schwan said: “We have achieved good results in the first half, primarily thanks to the demand for our new medicines and Covid-19 tests.

“I’m particularly excited about the significant progress we made in our product pipeline, including very promising study results for Tecentriq in early-stage lung cancer, as well as additional positive data for Evrysdi in spinal muscular atrophy and for Covid-19 medicines.”

Sales in the company’s Diagnostics Division surged by 51% to $9.9bn (CHF9bn) driven by increased demand for Covid-19 tests and robust momentum in routine testing.

Roche acquired the US company GenMark Diagnostics for $1.9bn in April, boosting its molecular lab offerings and vision to combat infectious diseases and antibiotic resistance.

The core operating profit of Roche rose by 4% at CER to $12.65bn (CHF11.65bn) in H1 2021.

Meanwhile, the diluted core earnings per share (EPS) increased from $11.34bn (CHF10.44bn) in H1 2020 to $11.74bn (CHF10.56bn) this year, indicating a growth of 6% at CER and 1% in Swiss currency.

Roche confirmed its outlook for this year and anticipates a low to mid-single-digit range increase in sales, at constant exchange rates, even with the ongoing biosimilars impact.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology